Titan Pharmaceuticals to Present at 14th Annual BIO CEO & Investor Conference
SOUTH SAN FRANCISCO, CA -- (MARKET WIRE) -- 02/06/12 -- Titan Pharmaceuticals, Inc. (OTCBB: TTNP) today announced that company President Sunil Bhonsle will present during the 14th Annual BIO CEO & Investor Conference on Monday, February 13, 2012 at 9 a.m. ET. The presentation will be webcast from the conference being held in New York City.
To access the presentation online, please visit www.titanpharm.com or http://www.veracast.com/webcasts/bio/ceoinvestor2012/51103193.cfm. A replay of the webcast will be made available through the link on the Titan website approximately 24 hours after the live presentation and the replay will be archived for 90 days.
About Titan Pharmaceuticals
For information concerning Titan Pharmaceuticals, Inc., please visit the company's website at www.titanpharm.com.
The press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to the Company's development program and any other statements that are not historical facts. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to difficulties or delays in development, testing, regulatory approval, production and marketing of the Company's drug candidates, adverse side effects or inadequate therapeutic efficacy of the Company's drug candidates that could slow or prevent product development or commercialization, the uncertainty of patent protection for the Company's intellectual property or trade secrets, and the Company's ability to obtain additional financing. Such statements are based on management's current expectations, but actual results may differ materially due to various factors, including those risks and uncertainties mentioned or referred to in this press release.
CONTACT: Titan Pharmaceuticals, Inc. Sunil Bhonsle President 650-244-4990 Pure Communications Dan Budwick 973-271-6085 firstname.lastname@example.org
Source: Titan Pharmaceuticals, Inc.
Released February 6, 2012